View Older Stories
-
Canaccord Reiterates Buy Rating on Hims and Hers (HIMS)
-
Evercore ISI on Hims and Hers (HIMS): 'Receding Profit Outlook'
-
After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
-
Hims & Hers Health, Inc. (HIMS) Misses Q2 EPS by 32c, Beats on Revenue; Offers FY26 Revenue Guidance
-
Truist on Hims and Hers (HIMS): 'renewal subscribers now represent a growing share of the branded GLP-1 base relative to new subscribers'
-
Hims & Hers launches AI-integrated app for women's weight loss
-
FTC sues Hims & Hers; company vows to fight the claims
-
Hims & Hers responds to FTC lawsuit, says claims are "baseless"
-
FTC Sues Hims & Hers Health In Federal Court
-
Canaccord on Hims and Hers: see "HIMS shares outperforming the major indices by several hundred basis points"
-
Hims & Hers Health shares jump on FDA's push to expand BPC-157 access
-
FDA Committee Recommends To Widen Access To Bpc-157 Peptide
-
Hims & Hers chief accounting officer to resign in October
-
Truist Reiterates Hold Rating on Hims and Hers (HIMS)
-
Hims and Hers (HIMS) PT Raised to $37 at BofA Securities
-
Hims & Hers units enter $400M receivables deal with JPMorgan
-
Hims and Hers (HIMS) PT Raised to $36 at BofA Securities, 'This update is negative for the HIMS'
-
Hims and Hers (HIMS) PT Raised to $40 at Canaccord
-
Oral Wegovy reaches 33% of total prescriptions by May
-
Hims and Hers (HIMS) PT Raised to $39 at Barclays, 'Our Proprietary Data Points to Sharp Inflection'
-
Leerink on Hims and Hers (HIMS): 'We still think the stock will be more driven by the puts and takes of near-term GLP-1 profitability'
-
Canaccord Reiterates Buy Rating on Hims and Hers (HIMS)
-
Leerink Reiterates Market Perform Rating on Hims and Hers (HIMS)
-
HIMS adds eight wellness partners to subscriber benefits program
-
Hims & Hers Health, Inc. (HIMS) Spikes 2.8% as Board of Directors David Wells Buys $1.1mn Worth of Stock
-
Hims and Hers (HIMS) PT Lowered to $25 at BofA Securities
-
Hims and Hers (HIMS) PT Raised to $23 at Truist Securities
-
Hims & Hers launches generic semaglutide in Canada at $149 monthly
-
Hims & Hers launches generic semaglutide in Canada at $149 monthly
-
Hims and Hers (HIMS) PT Lowered to $28 at BofA Securities
-
Hims and Hers (HIMS) PT Lowered to $24.50 at Jefferies, 'execution story now'
-
Hims and Hers (HIMS) PT Lowered to $30 at BofA Securities
-
Hims & Hers stock tumbles as revenue, EBITDA miss estimates
-
BTIG on Hims and Hers (HIMS): 'will need to aggressively manage sales and marketing costs'
-
Hims and Hers (HIMS) PT Raised to $25 at TD Cowen
-
Hims and Hers (HIMS) PT Raised to $35 at Needham
-
Hims and Hers (HIMS) PT Raised to $35 at Needham
-
Hims and Hers (HIMS) PT Raised to $28 at Citi
-
Evercore ISI on Hims and Hers (HIMS): 'Prognosis Unclear'
-
Hims and Hers (HIMS) PT Raised to $32 at Canaccord
-
Hims & Hers Health, Inc. (HIMS) Misses Q1 EPS by 41c, Misses on Revenue; Offers FY26 Revenue Guidance
-
Hims & Hers earnings preview: BofA says company lost GLP-1 share in 1Q
-
Hims & Hers Health, Inc. (HIMS) call put ratio 3.4 calls to 1 put with a focus on 1K contracts of January 105 calls into quarter results
-
Truist on Hims and Hers (HIMS): 'NVO Partnership Off to a Solid Start'
-
Hims & Hers Health, Inc. (HIMS) spreader of May calls into quarter results
-
Hims & Hers Health, Inc. (HIMS) spreader of 2K contracts of May 28 and 30 calls into quarter results
-
Amazon Pharmacy adds same-day delivery for Ozempic pill
-
JPMorgan Starts Hims and Hers (HIMS) at Overweight
-
Hims and Hers (HIMS) PT Raised to $32 at BofA Securities
-
Hims & Hers expands platform to include Eli Lilly weight loss medications

